Circulating Tumor Cell Count Reliable in Determining Best Treatment Approach for Metastatic Breast Cancer

Published by Jason Butcher on

Circulating tumor cell count is a reliable biomarker for choosing between chemotherapy or endocrine therapy for patients with HER2-negative metastatic breast cancer, according to a recent study published in JAMA Oncology (2020 Nov 5. doi:10.1001/jamaoncol.2020.5660). 

“The choice between chemotherapy and endocrine therapy as first-line treatment for [HER2-negative] metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis,” wrote François-Clément Bidard, MD, PhD, Department of Medical Oncology, Institut Curie, Saint-Cloud, France, and colleagues.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.